



## **Pluristem to Present at Two Cell Therapy Conferences in January 2015**

***Presentations focus on delivery of cell therapy from manufacturing facility to patient bedside aided by Company's proprietary point-of-care cell thawing device***

**HAIFA, ISRAEL, January 13, 2015** --[Pluristem Therapeutics Inc.](#) (NasdaqCM, TASE: PSTI), a leading developer of placenta-based cell therapy products, announced today it will be presenting at two cell therapy conferences during the month of January. Both presentations describe the use of Pluristem's proprietary cell thawing device to provide rapid, uniform thawing of its PLacental eXpanded (PLX) cells at the point-of-care prior to patient administration.

On January 20, 2015, Lior Raviv, Team Leader of Product Development at Pluristem, will present at ECI's [Fourth Annual Scale-Up and Manufacturing of Cell-Based Therapies Conference](#) in San Diego. His presentation is titled "Bringing cell therapy up to patient bedside- The development of an automated and controlled point-of-care cell thawing device". Nadav Eshkol, Process Engineering Team Leader, will present a poster titled "From pilot scale to mass production- Bioreactors scale up in cell therapy industry".

On January 27 and 28, 2015, Dr. Ohad Karnielli, VP Technology and Manufacturing at Pluristem, will present and participate in a panel discussion at the [Cell & Gene Therapy Forum 2015](#) in Washington DC. Dr. Karnielli will be a panel member in the conference's session titled 'Clinical/commercial strategy updates: Preparing MSCs and other stem cell therapeutics for market', on January 27. On January 28, Dr. Karnielli will deliver a presentation titled "Controlling cell delivery, from manufacturing to the patient via shipment, storage, thawing and routes of administration", during the conference's session titled "Can next-generation storage technologies unlock regenerative medicine markets?"

### **About Pluristem Therapeutics**

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company's proprietary three-dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit [www.pluristem.com](http://www.pluristem.com), the content of which is not part of this press release.

### **Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, forward-looking statements are used in this press release when we discuss the use of our cell thawing device. For example, forward-looking statements are used in this press release when we discuss the use of our cell thawing device. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact:

Pluristem Therapeutics Inc.  
Karine Kleinhaus, MD, MPH  
Divisional VP, North America  
1-914-512-4109

[karinek@pluristem.com](mailto:karinek@pluristem.com)